Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...

Merck & Co has said building its cardiovascular ... suggesting it is in the same ballpark for efficacy as its PCSK9 rivals. Lead investigator Christie Ballantyne, of Baylor College of Medicine ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

Merck’s MRK stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals industry. The stock has also underperformed the sector and the S&P 500 ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

German pharma and technology giant Merck has announced a €5 million (£4.2m) investment in Scotland that will create further jobs at its diagnostics and blood typing facility in Livingston.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...